Author/Authors :
Soheilifar, Mohammad Hasan Research Center for Molecular Medicine and Genetics - School of Medicine - Hamadan University of Medical Sciences, Hamadan, Iran , Moshtaghian, Abdolvahab Deputy of Research and Technology - Semnan University of Medical Sciences, Semnan, Iran , Maadi, Hamid Department of Medical Genetics - Faculty of Medicine and Dentistry - University of Alberta, Edmonton, Canada , Izadi, Fereshteh Department of Plant Breeding and Biotechnology - Sari Agricultural Sciences and Natural Resources University (SANRU), Sari, Iran , Saidijam, Massoud Research Center for Molecular Medicine and Genetics - School of Medicine - Hamadan University of Medical Sciences, Hamadan, Iran
Abstract :
Context: Colorectal cancer (CRC) is among the most common cancers in the world. Despite the existence of different treatment
strategies such as chemoradiation and surgery, CRC therapy still remains a significant challenge as a result of the existence of cancer
stem cells (CSCs).
Evidence Acquisition: This review is comprised of research and review studies published in valid databases such as PubMed, ScienceDirect,
Medline, Google Scholar, and Scopus, using the following keywords: BMI1, cancer stem cell, microRNA, and colorectal
cancer.
Results: BMI1 (B cell-specific Moloney murine leukemia virus integration site 1) is a key component of polycomb repressor complex 1
(PRC1) and plays a significant role in CSCs self-renewal in various types of cancer including CRC. It has been proven that BMI1, in association
with deregulated microRNAs (miRNAs), can promote cell cycle progression as well as epithelial to mesenchymal transition
(EMT) in cancer.
Conclusions: BMI1 is a colon stem cell marker that is up-regulated in colon CSCs and can be taken as a promising target for CRC
therapy. This review describes the role of BMI-1 in the self-renewal of CSCs and EMT in association with miRNA dysregulation (with
emphasis on CRC).
Keywords :
Colorectal Cancer , miRNA , Cancer Stem Cell , BMI1
